EYOSON GROUP Co-Drafts Official Bovine Spleen Peptide Standard
We are proud to announce that the Group Standard T/UNP 661—2025: Bovine Spleen Peptide, officially issued by the China UN Procurement Promotion Association, has now come into effect. As a core drafting member, Xiamen Yuanzhidao Biotechnology Co., Ltd.—a subsidiary of EYOSON GROUP and sister company to Pepdoo (Xiamen) Co., Ltd.—played a pivotal role in shaping this industry-defining specification.
This achievement highlights EYOSON GROUP’s deep-rooted expertise in precision enzymatic hydrolysis and marks another milestone in the Group’s commitment to leading innovation and standardization in bioactive peptides.
A Landmark in Industry Standardization
The release of this group standard represents the first unified, scientific framework for the production process, quality specifications, and testing methods of bovine spleen peptides. It fills a critical regulatory gap, ensuring consistency, safety, and efficacy of this bioactive ingredient—while providing a strong foundation for the healthy development of the functional peptide industry.
EYOSON GROUP’s Core Contributions
As a core drafting organization, EYOSON GROUP’s extensive scientific and industrial experience was fundamental in the establishment of the standard’s technical parameters and quality benchmarks. Our strengths include:
- Advanced Processing Technologies: Mastery of directional enzymatic hydrolysis and membrane purification technologies ensures precise molecular weight distribution and active peptide enrichment.
- Rigorous Quality Control: A full-spectrum quality management system—from raw materials to finished product—uses high-performance liquid chromatography (HPLC), mass spectrometry, and other advanced tools for real-time analysis and control.
- Bioactivity Preservation: Our production processes are designed to preserve and enhance key functional properties such as immunomodulatory activity through meticulous structure–activity research.
- Innovation-Driven R&D: Continuous investment in research allows us to refine process parameters and push the boundaries of peptide performance and application.
These capabilities directly contributed to the scientific and forward-looking nature of the new bovine spleen peptide standard.
Leading the Future of Precision Peptides
EYOSON GROUP’s role in the formulation of the Bovine Spleen Peptide standard is a clear demonstration of our industry leadership in bioactive peptides and precision peptide technologies. As a technology-driven enterprise, we continue to build on several strategic pillars:
- Full Industrial Chain Integration: From raw material selection and core process development to large-scale manufacturing and strict quality control, we operate a fully integrated production model for peptide-based health ingredients.
- Academia–Industry Synergy: Close collaboration with leading research institutes and universities ensures efficient translation of scientific breakthroughs into real-world applications.
- Relentless Innovation Investment: With over 150 patents in bioactive peptides, EYOSON GROUP holds one of the strongest IP portfolios in the industry—empowering constant evolution in peptide preparation, validation, and application.
Commitment to High-Quality Health Solutions
The implementation of the bovine spleen peptide standard marks a significant step forward for the peptide industry. As a core contributor, EYOSON GROUP remains committed to:
- Advancing greener, more efficient peptide production technologies
- Uncovering the full health potential of bovine spleen peptide and other functional peptides
- Promoting open collaboration and knowledge-sharing across the industry
- Delivering high-quality, trustworthy health solutions to global customers
Toward a Healthier Future, Powered by Innovation
At EYOSON GROUP, we see technological innovation as the spear, and quality as the shield. With this dual commitment, we will continue to explore the vast potential of precision peptides—driving forward the vision of a Healthier China and a Healthier World.
